NASDAQ: EWTX

Edgewise Therapeutics, Inc.

Healthcare | Biotechnology

No licensed closing price on file for EWTX. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

Edgewise Therapeutics, Inc. (NASDAQ: EWTX) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-19 20:43 UTC.

What Edgewise Therapeutics, Inc. does

Edgewise is a biopharmaceutical company that develops medicines for serious muscle diseases using a proprietary drug discovery platform focused on muscle biology and small molecule engineering. The company's most advanced program, sevasemten, is an orally administered drug designed to treat muscular dystrophies including Duchenne and Becker by preventing contraction-induced muscle damage, and is currently in late-stage clinical trials with regulatory designations from the FDA.

Summarized from Edgewise Therapeutics, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Key facts

Charts

Charts are in the appInteractive charts for EWTX are available in Oxford Ledge.
Open EWTX in Oxford Ledge →

SEC Filings

SEC EDGAR ↗

Recent Insider Activity (last 90 days)

Source: SEC EDGAR · Filed 2026-10-02

2026-10-02DirectorAward308—
2026-08-17CMOStock Option (Right to Buy)Award65,000—
2026-08-17Chief Financial OfficerStock Option (Right to Buy)Award48,750—

Top Institutional Holders (latest 13F)

Source: SEC EDGAR · As of 2026-Q2

ORBIMED ADVISORS LLC15,518,492$630.52M0.0%
Paradigm Biocapital Advisors LP10,215,455$415.05M+38.7%
RA CAPITAL MANAGEMENT, L.P.8,392,730$341.00M-19.5%

View QoQ ownership changes →Full institutional ownership →

Recent 8-K Events (parsed from SEC filings)All events →

Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

2025-11-10Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →
2024-05-07Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →
2023-03-06Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersJonathan FoxEstimatedSEC 8-K →

Company news

View all →

William Blair Initiates Coverage On Edgewise Therapeutics with Outperform Rating
Benzinga2026-10-16POS
Does Edgewise Therapeutics’ (EWTX) HFpEF Expansion Quietly Redefine Its Core Cardiovascular Strategy?
Yahoo2026-10-15
Edgewise Therapeutics Doses First Patient in Phase 2 EQUINOX-HFpEF Trial of EDG-15400
Yahoo2026-10-08
Edgewise Therapeutics Doses First Participant In EQUINOX-HFpEF Study Of EDG-15400 To Treat Adults With Symptomatic Heart Failure With Preserved Ejection Fraction
Benzinga2026-10-08
Edgewise Therapeutics (EWTX) Sets EDG 7500 Focus Call, Is It Still 20% Below Fair Value?
Yahoo2026-10-03

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for EWTX and 5,000+ tickers.

Create a free account — keep EWTX

For your agent

GET /api/data?ticker=EWTX

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt